section name header

General Reference

Nejm 1985;313:1059

Pathophys and Cause

Cause:Hepatitis A virus, a pico-RNA enterovirus

Pathophys:Only in humans; because it is an enterovirus, incidence up in late summer and early winter; 45% of adults have had it (Nejm 1976;95:755); increased incidence in gay males (Nejm 1980;302:438)

Epidemiology

Fecal/oral contact with infected persons for a week after jaundice appears; can be transmitted up to a year after clinical disease (Jama 1958;200:365); occasionally parenteral; higher incidence in parents of day care center children, children are often asx (Nejm 1980;302:1222)

In US, incidence has plummeted w childhood immunization now in majority of states (Jama 2005;294:194)

In developing countries, 3/1000/mo incidence for 1st-class hotel users, 20/1000/mo for community living guests; thus is most frequent preventable infection in travelers (Jama 1994;272:885)

Signs and Symptoms

Sx:

15-40 d incubation period (Am J Med 5/62)

In children, only 5-15% get sx

Malaise (48% in children/63% in adults), anorexia (41%/42%), abdominal pain (48%/37%), fever and/or chills (41%/32%), jaundice (65%/88%), diarrhea (58%/18%), dark urine (58%/68%), light stools (58%/58%), nausea and vomiting (65%/26%)

Si:Jaundice, though anicteric form also common and more benign

Course

Benign, 15% morbidity and rare (0.3%) mortality (Ann IM 1998;128:111); sx peak 2 wk after onset and take about 4 wk to clear; relapse in 6% at 1-3 mo (Ann IM 1987;106:221)

Complications

Fulminant hepatitis, relapsing hepatitis, no chronic active hepatitis (Eric Mast, CDC 11/95)

r/o other pre-, intra-, and post-hepatic causes of jaundice, including hepatocellular disease, obstructive causes

other viral hepatitis non-A, non-B hepatitis like HEPATITIS E virus infection, an enterovirus that causes only acute hepatitis like hep A (Nejm 2004;351:2367) but that sometimes evolves to acute hepatic failure, an enterovirus spread via water sources esp in equatorial areas (Virol 1993;4:273), eg, 80% of Indians have it; and in pregnant women, who have a 25% mortality. Effective recombinant vaccine (rVEV) available as 3-shot series (Nejm 2007;356:1895, 949)

Lab and Xray

Lab:

Chem:Typical hepatitis enzyme picture w ALT (SGPT) > AST (SGOT) > LDH > alkaline phos levels

Serol:Hepatitis A IgM antibody present when 1st sx present (Ann IM 1982;96:193); later IgM goes negative and IgG appears and stays

Treatment

Rx:

Prevent by: avoiding fecal contamination

Vaccine, inactivated (Havrix, or Vaqta) (Nejm 1997;336:197; Med Let 1995;37:51; Jama 1995;273:906; 1994;272:885; Nejm 1992;327:453) 2-shot (1 cc w 1440 ELU im) series for adults 6-12 mo apart, 3-shot (0.55 cc, 720 ELU im) series for children at 0, 1 mo, and 6-12 mo; 100% effective, no need to screen titers if born after 1945, may be useful postexposure (80% efficacy) (Lancet 1999;353:1136) but not clearly better than IgG (ACP J Club 1999;131:45), how often to reboost unclear; cost, $55/dose

Prophylax w IgG 0.02 cc/kg up to 2 cc im if exposed, or vaccinate (Nejm 2007;357:1685)